Novavax (NASDAQ:NVAX) Stock Breaks Above Fifty Day Moving Average – Time to Sell?

Novavax, Inc. (NASDAQ:NVAX)’s stock price crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $10.43 and traded as high as $10.62. Novavax shares last traded at $10.47, with a volume of 2,790,195 shares.

Novavax News Roundup

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Sanofi milestone payment provides an immediate catalyst. Novavax earned a $125 million payment after Sanofi dosed the fifth patient in a Phase 3 European trial of an influenza-COVID-19 combination vaccine using Novavax’s Nuvaxovid. The payment strengthens Novavax’s cash position and validates the commercial potential of its Sanofi partnership. Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
• Positive Sentiment: Combination-vaccine opportunity could create additional long-term value. Sanofi’s Phase 3 study is testing Nuvaxovid alongside its high-dose flu vaccine in adults aged 60 and older. Positive results could lead to additional milestones and future royalty opportunities for Novavax in the combined flu and COVID-19 market, which the company estimates exceeds $10 billion. Novavax Earns $125 Million Milestone From Sanofi’s Phase 3 Vaccine Trial in Europe
• Neutral Sentiment: Third-quarter results are scheduled for November 5. Novavax plans to release its financial results before the U.S. market opens and hold a conference call at 8:30 a.m. ET. The report may provide updates on operating performance, cash resources, vaccine demand and the Sanofi collaboration. Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
• Negative Sentiment: Analysts are flagging potential earnings weakness ahead of the report. A Zacks analysis says NVAX lacks the usual combination of earnings and revenue-estimate trends associated with a likely beat, raising the risk of a disappointing third-quarter result and increased volatility around the release. Novavax May Report Negative Earnings

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NVAX. Weiss Ratings reiterated a “sell (d)” rating on shares of Novavax in a research note on Tuesday, August 4th. Citigroup reissued a “sell” rating and issued a $8.00 target price (up from $7.00) on shares of Novavax in a research note on Thursday, October 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Novavax in a report on Tuesday. Zacks Research lowered shares of Novavax from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Novavax has an average rating of “Hold” and a consensus target price of $12.33.

Novavax Price Performance

The business has a 50-day simple moving average of $10.43 and a two-hundred day simple moving average of $9.29. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -6.89 and a beta of 2.44.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%. The business had revenue of $56.70 million for the quarter, compared to analysts’ expectations of $52.51 million. During the same quarter in the prior year, the business earned $0.62 EPS. The firm’s revenue for the quarter was down 76.2% on a year-over-year basis. As a group, equities analysts anticipate that Novavax, Inc. will post -0.50 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novavax

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new stake in shares of Novavax during the 2nd quarter worth about $8,004,000. Edgestream Partners L.P. bought a new stake in shares of Novavax during the 1st quarter worth about $4,234,000. Renaissance Technologies LLC bought a new stake in shares of Novavax during the 1st quarter worth about $4,049,000. Squarepoint Ops LLC acquired a new position in Novavax in the 2nd quarter valued at about $1,258,000. Finally, First Trust Advisors LP grew its stake in Novavax by 37.7% in the 1st quarter. First Trust Advisors LP now owns 409,328 shares of the biopharmaceutical company’s stock valued at $3,332,000 after buying an additional 112,009 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.